Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7759065 in advanced solid tumors
NCT06488716Phase 1Terminated
- Sponsor
- Genentech
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of RO7759065 in solid tumor (4 arms), sponsored by Genentech. Primary endpoints: Dose Limiting Toxicity at 5 years and Adverse Events at 5 years. Started Dec 2024; status: terminated.
02
Drugs
RO7759065
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06488716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488716.